抗体 (JP Patent Analysis Report)
The Technical Field "抗体" had 1,188 patent application filings in the most recent period (2022-01-01 to 2022-08-31). This is a significantly decreased of -1,039 filings (-46.7%) over 2,227 they had in the same period of the previous year (2021-01-01 to 2021-08-31).
The highest number of filings in 2016 with 4,204 cases, and their lowest number in 2022 with 1,260 cases.
The mean of the number of filings over the last 5 years (2018 to 2023, 15,708 cases in total) is 2,618, and the median is 3,214. The coefficient of variation (standard deviation/mean) is 0.6, and there have been big fluctuations in the number of filings from year to year.
| Index | Value |
|---|---|
| Average | 2,618 patents |
| Std Dev | 1,459 |
| COV | 0.6 |
The number of filings has been decreasing for the last 3 years (2020 to 2023).
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 1,260 cases | -61.5 % |
| 2021 year | 3,269 cases | +3.45 % |
| 2020 year | 3,160 cases | -18.54 % |
This report provides the latest patent analysis information (the IP landscape, including a patent map) on the patent search results of the JP patent database for 抗体 for the period of the last 10 years (2014-01-01 to 2024-04-30). You can compare the information in this report with the trends in your competitors’ patent filings and technologies, and use it to search for important patents.
This service provides, free of charge, a patent analysis report based on the latest patent data (Japanese, U.S., European, and PCT application publications) for use in patent searches, patent analysis, and IP landscaping. The service is offered by "Patent Integration" a firm specializing in patent search/patent analysis.
This report includes basic information to help you understand the IP strategy and management of 抗体, such as changes in the number of patents/patent applications they have filed, comparisons of the numbers of patents/patent applications filed by their peers and competitors, their top coapplicants (joint research partners, alliance partners), and their most important patents. It can be used in various intellectual property business operations such as IP landscaping, patent search/patent analysis, preparation of intellectual property business evaluation reports, selection of M&A candidates, and selection of alliance partners.
He is a patent attorney at a patent office. He specializes in invention counseling, patent filing, and intellectual property strategies for start-up companies and new businesses in the fields of software, information technology and artificial intelligence. He runs a patent course for beginners on Udemy, an online course provider.
After studying physics at the University of Tokyo as a doctoral student, he was engaged in intellectual property analysis and technology trend research as an in-house patent attorney at a precision equipment manufacturer and at Toyota Central R&D Labs. Inc..
Introduction
The concept of the "IP landscape" (IPL) has been attracting attention recently.
An IP landscape is not limited to patent information, but also integrates and analyzes business information (e.g., non-patent information such as papers, news releases, stock information, and market information). Intellectual-property-based business management is realized through the analysis of intellectual property information applied to the formulation of management strategies and business strategies. This is a comprehensive approach that includes but not limited to planning of open and closed strategies, selecting M&A candidates, searching for alliance partners, and formulating intellectual property strategies, through the exploitation of intellectual property information.
IP landscaping usually includes patent search and patent analysis. In patent search and patent analysis, it is important to grasp the market position of each company and the overall technological trends and development trends for each technology. More specifically, it is important to understand what intellectual property your own company and other companies hold, what the strengths and weaknesses of other companies are, and how other companies are trying to exploit their intellectual property. In other words, it is important to understand both the business strategy and the intellectual property strategy of each company.
After reading this search report, you may be interested in more detailed patent searches and patent analysis. We offer a service called Patent Integration, which is an integrated patent search and patent analysis service. With reasonable pricing and a simple user interface such that even beginners can quickly search for and analyze patent information by company or technology from a web browser, please consider using it for detailed patent searches, patent analysis, and IP landscaping.
Patent Integration has a patent-landscaping function that can visually represent a set of tens of thousands of patents/patent applications. This allows you to convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
抗体, Changes in the Number of JP Patents/Patent Applications
The changes in the number of patent filings of 抗体 over the last 20 years (JP) are shown below.
The change in the number of patents/patent applications is the most basic index in patent analysis. By examining the change in the number of patents/patent applications, you can see the status of technological development and R&D focus for each company or technology. It should be noted that since there is a one and a half year lag between the filing and the laying open of patent applications, it is not possible to analyze the situation more recently than one and half years prior to the present.
In this report, you can only see the change in the number of patents/patent applications by company or technology, whereas Patent Integration allows you to quickly compare the number of patent applications with your competitors in each technical field by cross-referencing with other keywords and patent classifications.
Search Set (Analysis Patents)
This patent analysis report was created for a patent search set of 31,178 cases retrieved by applying the following search formula and analysis period to the following patent database. Patent information such as a patent analysis result, a patent map, and a patent landscape can be freely used for patent searches, analysis, and work on intellectual property strategies, including IP landscaping.
抗体
Related Patent Analysis Report
A patent aanlysis report on the following synonyms was found in the technical term "抗体".
- 抗体 (Main page / Including the following synonyms)
Same industry / competition company information (JP)
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as 抗体 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Trends in filing of joint patent applications in the last 3 years (2022 to 2024).
Comparing the number of applications of each company, リジェネロン・ファーマシューティカルズ・インコーポレイテッド has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 17 cases, followed by 中外製薬株式会社 with 16 cases.
| Name | Cases |
|---|---|
| リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 17 cases |
| 中外製薬株式会社 | 16 cases |
| 東ソー株式会社 | 15 cases |
| ジェネンテックインコーポレイテッド | 14 cases |
| ノバルティスアーゲー | 12 cases |
| ザリージェンツオブザユニバーシティオブカリフォルニア | 10 cases |
| アムジエン・インコーポレーテツド | 9 cases |
| エフホフマン-ラロシュアーゲー | 6 cases |
| 武田薬品工業株式会社 | 3 cases |
Trends in filing of joint patent applications for the target period (2014 to 2024).
Comparing the number of applications of each company, ジェネンテックインコーポレイテッド has the highest number of joint applications in the last for the target period (2014 to 2024) with 771 cases, followed by リジェネロン・ファーマシューティカルズ・インコーポレイテッド with 601 cases.
| Name | Cases |
|---|---|
| ジェネンテックインコーポレイテッド | 771 cases |
| リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 601 cases |
| ノバルティスアーゲー | 449 cases |
| エフホフマン-ラロシュアーゲー | 407 cases |
| 中外製薬株式会社 | 332 cases |
| アムジエン・インコーポレーテツド | 287 cases |
| ザリージェンツオブザユニバーシティオブカリフォルニア | 252 cases |
| 東ソー株式会社 | 169 cases |
| 武田薬品工業株式会社 | 111 cases |
| アメリカ合衆国 | 72 cases |
| 国立研究開発法人科学技術振興機構 | 5 cases |
Same industry / competition company, Change in the Number of JP Patents
Below is a patent map showing changes in the number of applications for JP patents of 11 companies in the same industry over the past 20 years.
Top company information (JP)
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as 抗体 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Trends in filing of joint patent applications in the last 3 years (2022 to 2024).
Among the top coapplicants, リジェネロン・ファーマシューティカルズ・インコーポレイテッド has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 17 cases, followed by 中外製薬株式会社 with 16 cases.
| Name | Cases |
|---|---|
| リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 17 cases |
| 中外製薬株式会社 | 16 cases |
| ジェネンテックインコーポレイテッド | 14 cases |
| ノバルティスアーゲー | 12 cases |
| ザリージェンツオブザユニバーシティオブカリフォルニア | 10 cases |
| エフホフマン-ラロシュアーゲー | 6 cases |
| 武田薬品工業株式会社 | 3 cases |
Trends in filing of joint patent applications for the target period (2014 to 2024).
Among the top coapplicants, ジェネンテックインコーポレイテッド has the highest number of joint applications in the last for the target period (2014 to 2024) with 771 cases, followed by リジェネロン・ファーマシューティカルズ・インコーポレイテッド with 601 cases.
| Name | Cases |
|---|---|
| ジェネンテックインコーポレイテッド | 771 cases |
| リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 601 cases |
| ノバルティスアーゲー | 449 cases |
| エフホフマン-ラロシュアーゲー | 407 cases |
| 中外製薬株式会社 | 332 cases |
| ザリージェンツオブザユニバーシティオブカリフォルニア | 252 cases |
| 武田薬品工業株式会社 | 111 cases |
Top company, Change in the Number of JP Patents
Below is a ranking of the number of JP patent applications by 抗体’s top 7 coapplicants over the last 20 years.
Below is a patent map showing the changes in the numbers of JP patent filings by 抗体’s top 7 coapplicants over the last 20 years.
Top company Details (JP)
Trends in filing of joint patent applications with ジェネンテックインコーポレイテッド
抗体 filed 771 joint applications with ジェネンテックインコーポレイテッド for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 251 cases in total) is 41.8, and the median is 53.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2015 with 162 cases, and their lowest number in 2022 with 14 cases.
| Index | Value |
|---|---|
| Average | 41.8 patents |
| Std Dev | 26.0 |
| COV | 0.6 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 14 cases | -78.5 % |
| 2021 year | 65 cases | +47.7 % |
| 2020 year | 44 cases | -30.2 % |
Trends in filing of joint patent applications with 中外製薬株式会社
抗体 filed 332 joint applications with 中外製薬株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 139 cases in total) is 23.2, and the median is 18.5. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2016 with 68 cases, and their lowest number in 2022 with 15 cases.
| Index | Value |
|---|---|
| Average | 23.2 patents |
| Std Dev | 15.5 |
| COV | 0.7 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 15 cases | -16.67 % |
| 2021 year | 18 cases | -5.26 % |
| 2020 year | 19 cases | -50.0 % |
Trends in filing of joint patent applications with ノバルティスアーゲー
抗体 filed 449 joint applications with ノバルティスアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 186 cases in total) is 31.0, and the median is 30.0. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2015 with 85 cases, and their lowest number in 2022 with 12 cases.
| Index | Value |
|---|---|
| Average | 31.0 patents |
| Std Dev | 21.8 |
| COV | 0.7 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 12 cases | -55.6 % |
| 2021 year | 27 cases | -18.18 % |
| 2020 year | 33 cases | -31.2 % |
Trends in filing of joint patent applications with エフホフマン-ラロシュアーゲー
抗体 filed 407 joint applications with エフホフマン-ラロシュアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 182 cases in total) is 30.3, and the median is 34.5. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2015 with 73 cases, and their lowest number in 2022 with 6 cases.
| Index | Value |
|---|---|
| Average | 30.3 patents |
| Std Dev | 21.0 |
| COV | 0.7 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 6 cases | -81.2 % |
| 2021 year | 32 cases | -13.51 % |
| 2020 year | 37 cases | -26.00 % |
Trends in filing of joint patent applications with リジェネロン・ファーマシューティカルズ・インコーポレイテッド
抗体 filed 601 joint applications with リジェネロン・ファーマシューティカルズ・インコーポレイテッド for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 318 cases in total) is 53.0, and the median is 68.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2017 with 91 cases, and their lowest number in 2022 with 17 cases.
| Index | Value |
|---|---|
| Average | 53.0 patents |
| Std Dev | 32.6 |
| COV | 0.6 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 17 cases | -73.4 % |
| 2021 year | 64 cases | -15.79 % |
| 2020 year | 76 cases | -13.64 % |
Information on important patents (JP)
The following shows JP patents held by 抗体 that have had an invalidation trial against them demanded or an opposition filed against them by a third party, and 抗体’s JP patents/patent applications of high importance cited by Examiners in patent examination processes.
By noting the most important patents, you can obtain knowledge of the competitive business environment in which 抗体 is placed (e.g., whether it is a fiercely competitive environment or an oligopolistic market and the like). In general, it can be understood that a company with a large number of demands for invalidation trials is developing their business in a business environment where IP disputes are common.
If you want to search for more detailed information, you can use Patent Integration to retrieve and download by company cited patents/patent applications or patents undergoing invalidation trials. You can quickly extract important patents from a patent set that includes multiple competitors by cross-referencing with other keywords and patent classifications. Please consider using it for searches for important patents/patent applications.
Glossary
- Cited
- Indicates that the patent/patent application has been cited (by Examiners) in notices of reasons for rejection in the examination process of other (Japanese, U.S., or European) patent applications. The higher the number of citations, the more important the patent/patent application is considered to be.
- Request for invalidation trial
- Indicates that a third party has requested a procedure to invalidate the patent. It is likely to affect the business of third parties and is considered to be of high importance.
- Opposition
- Indicates that a third party has filed a petition with the Patent Office to hear the validity of the patent again. Like the trial for invalidation, it is considered to be of high importance.
- Information provision
- Indicates that a third party has provided the Patent Office with useful information for examination for the patent filed. It is usually considered to be of high importance because it is done to prevent the patent from being granted.
- Browsing request
- Indicates that a third party has requested the Patent Office to view the patent bag (a set of documents exchanged between the Patent Office and the applicant). The bag is often checked prior to trial for invalidation, opposition, and provision of information, and is considered to be a highly important patent.
Invalidationed Trial cases
List of latest Invalidationed Trial patents
In the last 3 years (2021-05-01 ~ 2024-04-30), there were 6 patents Invalidation Trial from third parties. The average number of Invalidation Trial is 1.0 times. The most recently Invalidation Trial patent is 特許7016341 "ＰＤ－１軸結合アンタゴニスト及びＴＩＧＩＴ阻害剤を使用するがんの治療方法" (Invalidation Trial day 2023-03-27) , next is 特許7083802 "グリコシル化された免疫グロブリンの調製方法" (Invalidation Trial day 2023-02-22) .
| - | No. | Title | Invalidation Trial days |
|---|---|---|---|
| 1 | 特許7016341 | ＰＤ－１軸結合アンタゴニスト及びＴＩＧＩＴ阻害剤を使用するがんの治療方法 | 2023-03-27 |
| 2 | 特許7083802 | グリコシル化された免疫グロブリンの調製方法 | 2023-02-22 |
| 3 | 特許6896700 | ワクチン組成物 | 2023-01-27 |
| 4 | 特許6278598 | 細胞傷害誘導治療剤 | 2022-03-31 |
| 5 | 特許6773929 | 細胞傷害誘導治療剤 | 2022-03-31 |
| 6 | 特許6738314 | ＢＣＭＡおよびＣＤ３に対する結合分子 | 2021-07-02 |
Top Patents/Patent Applications with the Highest Number of Invalidationed Trial
Of the patent applications filed in the last 10 years (2014-05-01 to 2024-04-30), 9 patents/patent applications were invalidation trial more than once in the examination process of other patent applications. The mean of the number of invalidation trial is 1.1. The most invalidation trial patent is 特許5906333 "プロタンパク質コンベルターゼスブチリシンケクシン９型（ＰＣＳＫ９）に対する抗原結合タンパク質" (2 times) , and the next most invalidation trial patent is 特許6896700 "ワクチン組成物" (1 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特許5906333 | プロタンパク質コンベルターゼスブチリシンケクシン９型（ＰＣＳＫ９）に対する抗原結合タンパク質 | 2 times |
| 2 | 特許6896700 | ワクチン組成物 | 1 times |
| 3 | 特許7016341 | ＰＤ－１軸結合アンタゴニスト及びＴＩＧＩＴ阻害剤を使用するがんの治療方法 | 1 times |
| 4 | 特許6035372 | 肺癌治療剤 | 1 times |
| 5 | 特許6258428 | 肺癌治療剤 | 1 times |
Oppositioned cases
List of latest Oppositioned patents
In the last 3 years (2021-05-01 ~ 2024-04-30), there were 18 patents Opposition from third parties. The average number of Opposition is 1.0 times. The most recently Opposition patent is 特許7270912 "アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬" (Opposition day 2023-11-13) , next is 特許7222347 "可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩" (Opposition day 2023-08-11) .
| - | No. | Title | Opposition days |
|---|---|---|---|
| 1 | 特許7270912 | アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬 | 2023-11-13 |
| 2 | 特許7222347 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | 2023-08-11 |
| 3 | 特許7210036 | アルツハイマー病および他の神経変性障害のためのバイオマーカーおよび診断方法 | 2023-07-20 |
| 4 | 特許7188087 | 一本鎖オリゴヌクレオチド | 2023-06-12 |
| 5 | 特許7117824 | モノクローナル抗体、検出方法、及び検出装置 | 2023-02-14 |
| 6 | 特許7060510 | 腫瘍マーカーの測定方法及び測定試薬 | 2022-10-26 |
| 7 | 特許7038664 | 操作された腫瘍溶解性ウイルス | 2022-09-15 |
| 8 | 特許7008337 | ヒト機能性角膜内皮細胞およびその応用 | 2022-08-09 |
| 9 | 特許6988481 | 一本鎖オリゴヌクレオチド | 2022-07-04 |
| 10 | 特許6944449 | 対象の細胞外液量状態のマーカーとしてのＭＲ−ｐｒｏＡＤＭ | 2022-04-06 |
Protested cases
List of latest Protested patents
In the last 3 years (2021-05-01 ~ 2024-04-30), there were 54 patents Protest from third parties. The average number of Protest is 1.2 times. The most recently Protest patent is 特表2021-527040 "カンプトテシンコンジュゲート" (Protest day 2024-03-25) , next is 特表2021-506842 "ポリペプチドの放射性標識" (Protest day 2024-01-31) .
| - | No. | Title | Protest days |
|---|---|---|---|
| 1 | 特表2021-527040 | カンプトテシンコンジュゲート | 2024-03-25 |
| 2 | 特表2021-506842 | ポリペプチドの放射性標識 | 2024-01-31 |
| 3 | 特表2022-504702 | 緩衝塩及びアミノ酸を含有する粉末、そのような粉末の栄養製品への再構成、並びにそのような栄養製品を使用する方法 | 2024-01-30 |
| 4 | 再公表2019/225568 | ガラス容器に封入された凍結乾燥製剤 | 2023-11-30 |
| 5 | 再公表2019/240288 | 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩 | 2023-11-29 |
| 6 | 特許7438604 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン | 2023-10-27 |
| 7 | 特開2023-053140 | チェックポイント遮断およびマイクロサテライト不安定性 | 2023-07-27 |
| 8 | 再公表2019/189882 | ＮＣＣ−ＳＴ−４３９抗原と特異的に反応するモノクローナル抗体およびその製造方法。 | 2023-07-20 |
| 9 | 特開2023-039448 | がんを治療するための、ＰＤ－１アンタゴニスト及びＶＥＧＦＲ／ＦＧＦＲ／ＲＥＴチロシンキナーゼ阻害剤の組合せ | 2023-07-12 |
| 10 | 特開2023-036582 | がんのための治療方法及び診断方法 | 2023-06-26 |
| 11 | 特開2023-011753 | チロシン硫酸化抗体変異体の除去のための精製方法；精製された組成物 | 2023-06-01 |
| 12 | 特開2023-025012 | 難治性ホジキンリンパ腫におけるニボルマブでのＰＤ－１遮断 | 2023-04-27 |
| 13 | 特表2021-520399 | ポリソルベートを使用するポリペプチドの精製方法 | 2023-03-31 |
| 14 | 特開2021-050215 | 皮下投与される抗ＩＬ−６受容体抗体 | 2023-03-30 |
| 15 | 特表2022-527809 | 抗体コード配列をセーフハーバー遺伝子座に挿入するための方法および組成物 | 2023-03-24 |
| 16 | 特許7439108 | ヒト心筋トロポニンＩに対する組換え抗体 | 2023-02-27 |
| 17 | 特開2022-188071 | 腫瘍を処置する方法において使用するための抗ＰＤ－１抗体 | 2023-02-17 |
| 18 | 特開2022-172083 | 癌のための治療方法及び診断方法 | 2023-01-17 |
| 19 | 特開2022-078021 | 癌のための治療方法及び診断方法 | 2022-12-07 |
| 20 | 特開2020-076762 | 細胞に結合可能な担体の製造方法 | 2022-11-16 |
Top Patents/Patent Applications with the Highest Number of Protested
Of the patent applications filed in the last 10 years (2014-05-01 to 2024-04-30), 102 patents/patent applications were protest more than once in the examination process of other patent applications. The mean of the number of protest is 1.4. The most protest patent is 特許6529907 "マイコプラズマ・ニューモニエの免疫学的検出法およびキット" (6 times) , and the next most protest patent is 特開2017-061467 "血管新生眼疾患を処置するためのＶＥＧＦアンタゴニストの使用" (5 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特許6529907 | マイコプラズマ・ニューモニエの免疫学的検出法およびキット | 6 times |
| 2 | 特開2017-061467 | 血管新生眼疾患を処置するためのＶＥＧＦアンタゴニストの使用 | 5 times |
| 3 | 特許6616332 | マイコプラズマ・ニューモニエの免疫学的検出法及びキット | 5 times |
| 4 | 特開2019-167366 | 血管新生眼疾患を処置するためのＶＥＧＦアンタゴニストの使用 | 4 times |
| 5 | 特許6616333 | マイコプラズマ・ニューモニエの免疫学的検出法およびキット | 4 times |
Inspectioned cases
List of latest Inspectioned patents
In the last 3 years (2021-05-01 ~ 2024-04-30), there were 614 patents Inspection from third parties. The average number of Inspection is 1.3 times. The most recently Inspection patent is 特表2021-505168 "操作されたＴ細胞の組成物を製造するための方法" (Inspection day 2024-03-26) , next is 特開2019-011372 "インターロイキン−６関連疾患の治療方法" (Inspection day 2024-03-26) .
| - | No. | Title | Inspection days |
|---|---|---|---|
| 1 | 特表2021-505168 | 操作されたＴ細胞の組成物を製造するための方法 | 2024-03-26 |
| 2 | 特開2019-011372 | インターロイキン−６関連疾患の治療方法 | 2024-03-26 |
| 3 | 特表2021-516049 | 組換えＴ細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法 | 2024-03-19 |
| 4 | 特許7334914 | ｃＤＮＡディスプレイを用いた新規イムノＰＣＲ法 | 2024-03-15 |
| 5 | 特表2021-529821 | イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 | 2024-03-13 |
| 6 | 特開2021-107422 | ドライアイの治療用医薬組成物 | 2024-03-08 |
| 7 | 特許7458678 | タンパク質同定のためのデコーディングアプローチ方法 | 2024-03-07 |
| 8 | 特開2022-105066 | がん免疫療法の臨床効果を予測する免疫学的バイオマーカー | 2024-02-27 |
| 9 | 特開2022-081543 | 抗ＴＲＥＭ２抗体及びその使用方法 | 2024-02-27 |
| 10 | 特表2023-521042 | 操作されたオリゴヌクレオチドを使用する標的化された阻害 | 2024-02-14 |
| 11 | 特表2021-510548 | 遺伝子治療のためのポリマーカプセル化されたウイルスベクター | 2024-02-14 |
| 12 | 特表2022-516496 | キメラ受容体ポリペプチド及びその使用 | 2024-02-14 |
| 13 | 特表2022-504702 | 緩衝塩及びアミノ酸を含有する粉末、そのような粉末の栄養製品への再構成、並びにそのような栄養製品を使用する方法 | 2024-02-09 |
| 14 | 特許4172777 | 外リンパ瘻の検出方法 | 2024-02-08 |
| 15 | 特表2023-526561 | 組成物およびその用途 | 2024-02-08 |
| 16 | 特許6000239 | 未変性Ｃｏｃｈｌｉｎ−ｔｏｍｏｐｒｏｔｅｉｎ（ＣＴＰ）に反応する抗体及びそれを用いたＣＴＰの測定方法 | 2024-02-08 |
| 17 | 特表2020-516615 | 上皮バリア機能障害の治療のためのタンパク質 | 2024-02-07 |
| 18 | 特許7434215 | 無細胞メチル化ＤＮＡを捕捉する方法及びその使用 | 2024-02-05 |
| 19 | 特表2021-500857 | 酵素補充療法用酵素を含む融合タンパク質 | 2024-02-02 |
| 20 | 特表2020-522489 | 養子細胞療法を用いる処置のための製造物品および方法 | 2024-01-30 |
Top Patents/Patent Applications with the Highest Number of Inspectioned
Of the patent applications filed in the last 10 years (2014-05-01 to 2024-04-30), 1,061 patents/patent applications were inspection more than once in the examination process of other patent applications. The mean of the number of inspection is 1.3. The most inspection patent is 特開2017-149726 "Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療" (46 times) , and the next most inspection patent is 特開2017-214435 "抗ＣＤ２０抗体の投与を含むＢ細胞リンパ腫の併用療法" (43 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特開2017-149726 | Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療 | 46 times |
| 2 | 特開2017-214435 | 抗ＣＤ２０抗体の投与を含むＢ細胞リンパ腫の併用療法 | 43 times |
| 3 | 特許6529907 | マイコプラズマ・ニューモニエの免疫学的検出法およびキット | 16 times |
| 4 | 特開2019-167366 | 血管新生眼疾患を処置するためのＶＥＧＦアンタゴニストの使用 | 10 times |
| 5 | 特許6241794 | 抗ＣＤ２０抗体の投与を含むＢ細胞リンパ腫の併用療法 | 9 times |
Cited cases
Top Patents/Patent Applications with the Highest Number of Cited
Of the patent applications filed in the last 10 years (2014-05-01 to 2024-04-30), 4,045 patents/patent applications were cited more than once in the examination process of other patent applications. The mean of the number of cited is 2.2. The most cited patent is 特許6232009 "ＣＤＲのアミノ酸置換により抗体の等電点を改変する方法" (37 times) , and the next most cited patent is 特許6196343 "免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド" (36 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特許6232009 | ＣＤＲのアミノ酸置換により抗体の等電点を改変する方法 | 37 times |
| 2 | 特許6196343 | 免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド | 36 times |
| 3 | 特許5902237 | ＰＳＭＡ結合性リガンド−リンカー結合体及び使用方法 | 31 times |
| 4 | 特許6082447 | 複数分子の抗原に繰り返し結合する抗原結合分子 | 30 times |
| 5 | 特許6778114 | イミド系タンパク質分解モジュレーター及び関連する使用方法 | 28 times |
Providing patent information to the media (newspapers, magazines, etc.)
"Patent Integration Report" is a web service provided by "Patent Integration Co., Ltd." operated by patent attorneys who are experts in intellectual property rights. Based on the latest patent data, this is one of the largest patent report services in Japan that provides information on technology trends in various companies and technology fields.
The purpose of this web service is to make intellectual property information familiar to many people, regardless of whether they have an interest in intellectual property rights, and to make use of it.
We actively provide various types of patent information that can be used in various media articles such as newspapers, magazines, and web media. Please feel free to contact us from "Inquiry form for details on the content of patent information that can be provided, conditions for provision, etc. Please contact us.
About this Site
All rights related to the data, documents and charts belong to "an integrated patent search/analysis service provider, Patent Integration". Please specify the source “Patent Integration Report, URL: https://patent-i.com/report/en/" when inserting them into in-house materials, external report materials, etc., regardless of whether they are paid or free of charge.
Patent data is obtained by aggregating and analyzing the latest patent data issued by the Patent Offices of respective countries and jurisdictions and by WIPO. Although we take great care in publishing and analyzing the results, we do not guarantee the correctness of the data. We appreciate your understanding.
If you have any concerns about this service, please feel free to contact us.
All rights to the data, documents, figures and tables are reserved by e-Patent. When publishing internal documents, external reports, etc. (whether paid or free of charge), please use the following URL: https://e-patent.co.jp/.
Please note the following points for use.
e-Patent will not be liable for any damages or losses arising from the use of the global patent application status, ranking information, or population search formula in the "SDGs Global Company Ranking from a Patent Perspective". Items with ● in front of the target are not supported at this time (judged to be difficult to approach from the patent information analysis).
Citation of patent application status and ranking information
There is no problem to cite patent application status and ranking information, but please clearly indicate "Source: e-Patent Co.
Graphs are image data.
Please note that the various graphs are image data, but we cannot provide them in text data.Scope of coverage for each goal/target
- Based on the description of each goal and target of the SDGs, we have set the scope of technologies to be covered based on our and e-Patent's past experience, etc. (in some cases, the search is based on social issues themselves). Therefore, please note that there is a possibility that this "SDGs Global Company Ranking from Patent Perspective" may not cover 100%.
- A population search formula is clearly indicated for each goal/target (database: Patent Integration). You may use the population search formula as it is, or you may improve it by yourself.
- This search covers patents and utility models, including both published and registered patents (design and design patents are excluded). The unit of count is the number of applications, not the number of patent families.
About the name collation and name control of applicants and right holders
- Company rankings are based on the results calculated by "Patent Integration", with Japanese organizations in Japanese and other companies in English (some are in Japanese).
- Company names may be the names of the companies at the time of application, but the results calculated by Patent Integration are used as is. Company names are used as they were at the time of application.
- Because of the fluctuation in the names of companies (i.e., applicant/right holder names in the patent information), there are cases where the same company appears more than once in the top 10. The number of applications filed by the same company in the top 10 is the total number of applications filed by the company.
Credit notation
・MeCab user dictionary for science technology term © National Bioscience Database Center licensed under CC Attribution-Share Alike 4.0 International
Our Commitment to Safety and Security
Patent Integration Co., Ltd. is committed to providing high-quality patent information based on the latest patent data on more than 45 million cases collected from the Patent Offices in Japan, the U.S., Europe, and Taiwan and from PCT publication. 
Patent Integration Co., Ltd. collects the patent data from the Patent Offices in Japan, the U.S., Europe, and Taiwan and from PCT publications to provide it widely in the form of reports so that anyone can check patent information and patent trends with confidence. 
Patent Integration Co., Ltd. is committed to various efforts to enhance the reliability of the information and to allow users to search patent information with confidence.